Shining Light on AAVs: Using Light Scattering Technologies to Solve Challenges in Characterization

With the rising clinical and commercial successes of AAV-based gene therapies, there is an ever-growing demand for robust, platform analytical technologies that can help ensure better product quality, safety, and efficacy. Size exclusion chromatography (SEC) and Field Flow Fractionation (FFF), coupled with multi-angle light scattering technologies (MALS), are rapidly emerging as transformative technologies for rapid and accurate characterization of AAV samples. Critical Quality Attributes (CQAs) such as capsid titer, genome titer, empty/full, % aggregation and purity of various AAV serotypes can all be obtained in a single measurement. This multi-attribute approach dramatically reduces operational costs and reduces drug development timelines.